

# Accepted Manuscript

Evaluation of the anti-malarial activity and cytotoxicity of 2,4-diamino-pyrimidine-based kinase inhibitors

Oraphan Phuangswai, Paul Beswick, Siriluk Ratanabunyong, Lueacha Tabtimmai, Praphasri Suphakun, Phongphat Obounchoey, Pimonwan Srisook, Natharinee Horata, Irina Chuckowree, Supa Hannongbua, Simon E. Ward, Kiattawee Choowongkomon, M. Paul Gleeson



PII: S0223-5234(16)30710-3

DOI: [10.1016/j.ejmech.2016.08.055](https://doi.org/10.1016/j.ejmech.2016.08.055)

Reference: EJMECH 8851

To appear in: *European Journal of Medicinal Chemistry*


Received Date: 18 June 2016

Revised Date: 23 August 2016

Accepted Date: 24 August 2016

Please cite this article as: O. Phuangswai, P. Beswick, S. Ratanabunyong, L. Tabtimmai, P. Suphakun, P. Obounchoey, P. Srisook, N. Horata, I. Chuckowree, S. Hannongbua, S.E. Ward, K. Choowongkomon, M.P. Gleeson, Evaluation of the anti-malarial activity and cytotoxicity of 2,4-diamino-pyrimidine-based kinase inhibitors, *European Journal of Medicinal Chemistry* (2016), doi: 10.1016/j.ejmech.2016.08.055.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.





ELSEVIER

## Evaluation of the anti-malarial activity and cytotoxicity of 2,4-diamino-pyrimidine-based kinase inhibitors.

Oraphan Phuangsawai<sup>a</sup>, Paul Beswick<sup>b</sup>, Siriluk Ratanabunyong<sup>c</sup>, Lueacha Tabtimmai<sup>c</sup>, Praphasri Suphakun<sup>c</sup>, Phongphat Obounchoey<sup>c</sup>, Pimonwan Srisook<sup>c</sup>, Natharinee Horata<sup>d</sup>, Irina Chuckowree<sup>b</sup>, Supa Hannongbua<sup>a</sup>, Simon E. Ward<sup>b,\*</sup>, Kiattawee Choowongkamon<sup>c</sup>, and M. Paul Gleeson<sup>a,\*</sup>

<sup>a</sup> Department of Chemistry, Faculty of Science, Kasetsart University, Bangkok 10900, Thailand

<sup>b</sup> School of Life Sciences, University of Sussex, Brighton, BN1 9QJ, United Kingdom

<sup>c</sup> Department of Biochemistry, Faculty of Science, Kasetsart University, Bangkok 10900, Thailand

<sup>d</sup> Faculty of Medicinal Technology, Huachiew Chalermprakiet University, Samut Prakarn 10540, Thailand

### ARTICLE INFO

#### Article history:

Received

Received in revised form

Accepted

Available online

#### Keywords:

2,4 diaminopyrimidine

*Plasmodium falciparum*

Antimalarials

Drug design

Tyrosine kinase inhibitors

K1 strain

JAK2 kinase

### ABSTRACT

A series of 2,4-diamino-pyrimidines have been identified from an analysis of open access high throughput anti-malarial screening data reported by GlaxoSmithKline at the 3D7 and resistant Dd2 strains. SAR expansion has been performed using structural knowledge of the most plausible parasite target. Seventeen new analogs have been synthesized and tested against the resistant K1 strain of *Plasmodium falciparum* (Pf). The cytotoxicity of the compounds was assessed in Vero and A549 cells and their selectivity towards human kinases including JAK2 and EGFR were undertaken. We identified compound **5n** and **5m** as sub-micromolar inhibitors, with equivalent anti-malarial activity to Chloroquine (CQ). Compounds **5d** and **5k**,  $\mu$ M inhibitors of Pf, displayed improved cytotoxicity with weak inhibition of the human kinases.

2009 Elsevier Ltd. All rights reserved.

### 1. Introduction

Malaria is a tropical infectious disease of humans and other animals caused by mosquito-borne parasites that include *Plasmodium falciparum* (Pf) and *Plasmodium vivax* (Pv). The former causes the greatest percentage of deaths due to its more severe symptoms. The disease is prevalent in tropical climates in the African and Asian sub-continent, affecting countries with less developed economies.<sup>1,2</sup> In 2015 the World Health Organization (WHO) reported that approximately 5.9 million of children under five years of age died from this infectious disease.<sup>3</sup> To reduce the ongoing issue of drug resistance, the current frontline treatment artemisinin is given as a combination only, yet there are signs that its efficacy is under threat.<sup>4-6</sup> New antimalarial drugs that target novel modes of action are therefore highly desirable to tackle this disease.<sup>7-11</sup>

The malaria parasite has a complex life cycle in which multiple kinase enzymes play an important role.<sup>12,13</sup> The target of the artemisinin has recently been suggested to be phosphoinositide 3-kinase (PfPI3K),<sup>14</sup> while the target of the


MMV development compound MMV390048 was proposed to be phosphoinositide 4-kinase (PfPI4K).<sup>15</sup> Additional protein kinases have also been implicated as possible targets.<sup>16-18</sup> A number of studies aimed at improving our understanding of the approximately 65 Pf specific kinases have been reported, many of which share considerable homology with human kinases.<sup>10,16,19</sup> This has led to kinase screening campaigns<sup>20</sup> and SAR studies on specific protein kinases, including PfCDPK1,<sup>21,22</sup> PfPK5<sup>23</sup> and PfPK7.<sup>24</sup> Nevertheless, it is not yet established which parasite kinase represents the most valid target,<sup>10</sup> or whether polypharmacology approaches could represent a useful approach, as found for cancer.<sup>25</sup>

In 2010, GlaxoSmithKline reported the results of screening of almost 2 million compounds to identify anti-malarial hits. Approximately 13,500 compounds with activity at *P. falciparum* (Pf) 3D7, multi-drug resistant Dd2 Pf strain and for cytotoxicity in the HepG2 cell line were released in the public domain.<sup>26</sup> In 2016, these hits were re-assessed at five Pf kinases (PfCDPK1, PfCDPK4, PfPK6, PfPK7 and PfMAPK2) and led to the identification of twelve series with potential for optimization.<sup>20</sup>

\* Corresponding authors. Tel.: +66-2-562-5555 extn. 2210; fax: +66-2-562-3955; e-mail: paul.gleeson@ku.ac.th, simon.ward@sussex.ac.uk

**Table 1**


Representative 2,4-diamino-pyrimidine hits identified from GSK HTS data.<sup>26</sup> *Pf* 3D7 (IC<sub>50</sub>, μM) and HepG2 cytotoxicity (% at 10 μM) are reported for: TCMDC-134115 (**1a**), TCMDC-134116 (**1b**), TCMDC-141384 (**1c**) and TCMDC-141383 (**1d**).



ID	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	X	3D7 IC <sub>50</sub> (μM)	HepG2 (%)
1a	CN	2-CONH <sub>2</sub>	Me	NCH <sub>3</sub>	0.009	99
1b	CN	2-CONH <sub>2</sub>	H	NCH <sub>3</sub>	0.040	43
1c	CONHCH <sub>3</sub>	3-NO <sub>2</sub>	H	NCH <sub>3</sub>	0.138	16
1d	CONHCH <sub>3</sub>	3-O <sup>t</sup> Pr	H	O	0.759	19

Our separate analysis of the GSK screening data led to the identification of a cluster of 2,4-diaminopyrimidine compounds with good activity, efficiency, physical properties and synthetic tractability (Table 1). The compounds display activity at the multidrug resistant Dd2 strain, whilst the HepG2 SAR suggests an anti-malarial vs cytotoxicity window of 50 fold is achievable (Table 1). **1b** is a confirmed inhibitor of *Pf*CDPK1 (0.012 μM), CDPK4 (0.089 μM) and *Pf*PK6 (0.054 μM). Host kinase interactions also require consideration as these could either lead to cytotoxicity or also potentially facilitate parasite eradication.<sup>17,27</sup>

The most probable human kinases targeted by **1a-d** include Janus kinase 2 (hJAK2),<sup>28</sup> Aurora A hAURKA,<sup>29,30</sup> Indeed, other hJAK and hAUR inhibitor classes have shown anti-malarial activity from repurposing studies.<sup>10,31</sup> The 2,4-diaminopyrimidine chemotype also appears in Epidermal growth factor (hEGFR),<sup>32</sup> and c-Jun N-terminal kinase (hJNK)<sup>33</sup> publications, as well as in patents targeting cancer-related pathways via hJAK<sup>34</sup> and hAURK (Figure 1).<sup>35</sup> Kinases inhibitors offer great potential as anti-malarials due to the wealth of chemical, biological and safety data amassed over many years to treat diseases in human, potentially reducing the development burden.



**Fig. 1.** 2,4-diamino-pyrimidines kinase inhibitors; TCMDC 134116,<sup>20</sup> TG101209,<sup>28</sup> SID103904601 ([www.pubchem.com](http://www.pubchem.com)) and covalent inhibitor WZ4002.<sup>32,36</sup>

**Table 2**

Sequence similarity, identity to probable *Pf* and host kinases.

ID	PDB ID	% similarity to <i>Pf</i> CDPK1	% identity to <i>Pf</i> CDPK1	Gatekeeper residue
<i>Pf</i> CDPK1	-	100	100	Thr
<i>Pb</i> CDPK1	3Q5I	91.8	87.0	Thr
hAUR	3UOL	45.1	25.3	Leu
hJAK2	4JI9	36.1	18.6	Met
hEGFR	3IKA	33.9	15.4	Met

In this study we report the design, synthesis and biological evaluation of new 2,4-diaminopyrimidine compounds. Our goal is to improve our SAR understanding of this series by screening additional analogs at the drug-resistant K1 *Pf* strain in the belief that molecules which target either individual, or a defined subset of kinases, offer potential new approaches to kill resistant strains. We also assess the cytotoxicity of the series using monkey kidney epithelial cell line (Vero), and the adenocarcinomic human alveolar basal epithelial cell line (A549). The human kinase activity of a subset are also evaluated for their potential to inhibit the human protein kinases: JAK2, JAK3 and EGFR.


## 2. Results

### 2.1. Design

The mode of action of compounds **1a-d** is unconfirmed, however *Pf*CDPK1, hAUR, hJAK and EGFR are probable targets. A focused library of 2,4-diamino-pyrimidines derivatives were prepared using established synthetic methods and directed towards improving our understanding the link between *Pf* activity, cytotoxicity and activity at key kinases in the hosts.

Crystal structures of the Plasmodium Berghei (*Pb*) CDPK1 homolog and the principal human targets were downloaded for analysis (Table 2). Despite dramatic differences in sequence identity, the conserved ATP binding site means inhibitors can have considerably cross reactivity.<sup>10</sup> A key difference between these targets is the moderately sized, non-polar gatekeeper for the human proteins, compared to the smaller, more polar Thr sidechain.<sup>37</sup>

We have undertaken modification to the chemotype at four different positions as highlighted in Figure 2. Region 1 exploits difference at the gatekeeper while region 2 (pyrimidine 4 position) targets differences within the kinase backpocket.<sup>38</sup> Modifications at the latter position have resulted in dramatic changes in the hAURA protein conformation though the flipping of the DFG-loop despite only subtle changes in substitution of the 4-position aniline.<sup>39</sup> Modifications at region 3 will induce subtle changes in ring conformation, which can benefit selectivity, while region 4 can be exploited to improve compound solubility.<sup>40</sup> Anti-malarial SAR shows that compounds with R1 = -CN have higher anti-malarial activity, however, this is mirrored by increases in the % cytotoxicity. We therefore evaluated the effect of incorporation of -H, -CN, -OMe and CONH<sub>2</sub>. A range of substituted anilines at the 2- and 4- positions were selected to exploit interaction toward the kinase solvent pocket and backpocket, respectively, and maintain reasonable molecule properties (Table 3). We attempted to bias the reagent selection to focus on lower MWT (mean=405 da) and clogP (mean=4.04). This was with the goal of increasing the likelihood of achieving better solubility and permeability and solubility, a pre-requisite for reliable phenotypic testing.



**Fig. 2.** Schematic (left) and docked model of 2,4-diamino-pyrimidines to PbCDPK1. The binding model of **5k** (carbons in grey) bound to the X-ray crystal structure of PbCDPK1 (3Q5I, magenta). The model was constructed using the JAK2-TG101209 complex (4JIA, cyan).<sup>41</sup> Hydrogen bonds to the hinge and structural waters are indicated by dotted lines.

## 2.2. Synthesis

Intermediates were synthesized using the methodology described in Scheme 1. **2a** was produced from the reaction of *p*-fluoronitrobenzene and piperazine in DMSO with the assistance of  $K_2CO_3$ . The amine product was hydrogenated to **3a** using Pd/C and  $H_2$ . Intermediates **3b** & **3c** were produced in the same manner.

Compound **1a** was synthesized following Scheme 2. The Cl at the 4-position of 5-cyano-2,4-dichloropyrimidine was substituted by *p*-aminobenzamide with the assistance of DIPEA giving intermediate **4a** (Scheme 2). Intermediate **4a** was reacted with **3a** assisted of DIPEA, leading to substitution at the 2-position. Compounds **5a-e** were synthesized in an analogous manner to **1a**. Compound **5e** was oxidized using hydrogen peroxide to yield compound **5f**. Compound **5g**, having an -OMe substituent at the 5-position was synthesized using the same protocol as **1a**.<sup>35</sup> Compounds **5h-r**, with H at the 5-position, were synthesized as follows; nucleophilic substitution at the 4-position of 2,4-dichloro pyrimidine was achieved using DIPEA base for  $R_2=3-SO_2NH_2$  and  $3-CH_3$ , a HCl promoted reaction for  $R_2=2-CONH_2$ . Nucleophilic attack at the corresponding 2-position was achieved using TFA to promote the reaction.

Nineteen compounds were synthesized (Table 3) with reaction yields varied from low (<30%) to excellent (>90%). Among the 19 compounds synthesized, compounds **1a** and **5j**. **1a** was originally reported in the study of Gamo et al.<sup>26</sup> and in the recent paper of Crothers et al.<sup>20</sup> **5j** was reported as a JNK2 inhibitor by Song et al targeted towards anti-cancer therapies.<sup>33</sup>

## 2.3. Biological testing

### 2.3.1. Anti-malarial activity

The titled compounds **1a**, **5a-r** were evaluated for their *in vitro* anti-malarial activity at the *Pf* K1 strain ( $EC_{50}$ ) using a hypoxanthine incorporation assay.<sup>42,43</sup> The compounds show a range in potency from 0.43-8.97  $\mu M$ . Compound **1a**, 0.009  $\mu M$  against the 3D7 strain, was found to be 3.9  $\mu M$  at the resistant K1 strain. Compounds **5n** and **5o** were 0.65 and 0.43  $\mu M$  respectively. In comparison, standards chloroquine displayed an

activity 0.57  $\mu M$ , Mefloquine 0.07  $\mu M$  and artemisin at 0.002  $\mu M$ .


Systematic analysis of the results presented in Table 3 suggests that compounds with -H at R1 are preferred for anti-malarial activity (as exemplified by **5a,r**). R2 position shows a preference for anilines with  $R_2 = 3-Me$  (**5a,r**) or  $2-CONH_2$  (**5k,m**). The R3 position does not display a clear preference towards the substituents employed. R4 shows a general preference towards Me-piperazine, compared to morpholine or the simpler substituted anilines.

### 2.3.2. Cytotoxicity


Compounds **1a**, **5a-r** were evaluated for their cytotoxicity at 10  $\mu M$  against the Vero cell line (ATCC CCL-81) using the method described by Hunt and co-workers.<sup>44</sup> The compounds show a range in potency from 25-96%. A degree of correlation between activity and cytotoxicity, with the most potent compounds (**5n,o**) also displaying high (94%) cytotoxicity. This compares to 50% for chloroquine, a standard anti-malarial treatment. Compounds **5d**, **5k** and **5m** display  $\mu M$  anti-malarial activity and low to moderate cytotoxicity at 31, 66 and 35%, respectively

Five compounds were taken forward for further assessment; potent but cytotoxic compounds (**5n,o**), moderately potent and cytotoxic compounds (**5k**), and moderately potent and weakly cytotoxic compounds (**5d,m**).  $EC_{50}$ s against the Vero (ATCC CCL-81) and A549 (ATCC CCL-185) cells using an MTT based method (Table 4).<sup>45</sup> The  $EC_{50}$ 's are in good agreement with the % cytotoxicity data, with **5d,k&m** demonstrating better activity than compounds **5n,o**. The A549 cytotoxicity data broadly mirrors those obtained in the Vero cell line. The lower  $EC_{50}$  values would be consistent with the higher expression of certain kinases in this disease tissue.<sup>46-50</sup>

No clear SAR is apparent at the R1 and R2 positions. Hydrogen is preferred at the R3 position and -H and morpholine are preferred at the R4 position. Compounds **5k** and **5m** show a reasonable balance of anti-malarial activity and cytotoxicity, approaching the desired 50-fold window.



**Scheme 1.** General scheme for the synthesis of anilines 5a-c. Reagents and conditions for **3a**: (a) K<sub>2</sub>CO<sub>3</sub>, DMSO, rt, 4-6 h, (b) Pd/C, H<sub>2</sub>, MeOH, rt, overnight.



**Scheme 2.** Synthetic approach used for the preparation of compounds **1a**, **5a-r**. Reagents and conditions for; **5a**: (a) DIPEA, n-BuOH, 110 °C overnight, (b) DIPEA, DMF, rt, 4 h; **5i**, (a) DIPEA, n-BuOH, 110 °C overnight, (b) TFA, isopropanol, overnight.

**Table 3**  
Activities and yields of compounds **1a**, **5a-r**.

ID	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	R <sub>4</sub>	% yield <sup>a</sup>	clogP <sup>d</sup>	MWT <sup>d</sup>	P.f. K1 IC <sub>50</sub> (μM)	Vero Cytotox. (%/50 μM)
<b>1a</b>	CN	<i>o</i> -CONH <sub>2</sub>	Me	Me-piperazine	25	4.7	443	3.93	94
<b>5a</b>	CN	<i>m</i> -SO <sub>2</sub> NH <sub>2</sub>	Me	Me-piperazine	23	3.1	479	5.56	91
<b>5b</b>	CN	3-Me & 4-Methylpiperazine	SO <sub>2</sub> NH <sub>2</sub>	H	15	3.1	479	NA <sup>e</sup>	33
<b>5c</b>	CN	<i>m</i> -SO <sub>2</sub> CH <sub>3</sub>	Me	Me-piperazine	26	4.4	478	4.72	92
<b>5d</b>	CN	<i>m</i> -SO <sub>2</sub> NH <sup>t</sup> Bu	Me	Me-piperazine	39	5.4	535	4.56	31
<b>5e</b>	CN	<i>m</i> -Me	Me	H	50 <sup>b</sup>	5.1	315	NA <sup>e</sup>	40
<b>5f</b>	CONH <sub>2</sub>	<i>m</i> -Me	Me	H	48 <sup>c</sup>	3.4	333	NA <sup>e</sup>	96
<b>5g</b>	OMe	<i>m</i> -SO <sub>2</sub> NH <sub>2</sub>	Me	Me-piperazine	91	3.1	484	5.26	88
<b>5h</b>	H	<i>o</i> -CONH <sub>2</sub>	Me	Me-piperazine	67	4.8	418	1.06	92
<b>5i</b>	H	<i>o</i> -CONH <sub>2</sub>	H	Me-piperazine	56	4.3	403	1.50	91
<b>5j</b>	H	<i>o</i> -CONH <sub>2</sub>	H	morpholine	11	4.2	390	4.39	68
<b>5k</b>	H	<i>m</i> -SO <sub>2</sub> NH <sub>2</sub>	Me	Me-piperazine	70	3.3	454	3.86	66
<b>5l</b>	H	<i>m</i> -SO <sub>2</sub> NH <sub>2</sub>	H	Me-piperazine	62	2.8	440	7.25	80
<b>5m</b>	H	<i>m</i> -SO <sub>2</sub> NH <sub>2</sub>	H	morpholine	75	2.7	427	8.97	35
<b>5n</b>	H	<i>m</i> -Me	Me	Me-piperazine	80	5.2	389	0.647	94
<b>5o</b>	H	<i>m</i> -Me	H	Me-piperazine	82	4.7	374	0.431	94
<b>5p</b>	H	<i>m</i> -Me	H	morpholine	79	4.6	361	NA <sup>e</sup>	74
<b>5q</b>	H	<i>m</i> -Me	Me	H	1.5	5.2	290	NA <sup>e</sup>	94
<b>5r</b>	H	4-phenylmorpholine	H	morpholine	20	4.0	433	NA <sup>e</sup>	25
Chloroquine					-	3.9	320	0.57	45
Mefloquine					-	4.1	378	0.07	-
Dihydroartemisinin					-	2.8	284	0.00254	-

<sup>a</sup>% yield obtained from di-substitution reaction at 2- and 4- position using condition <sup>b</sup> % yield obtained from oxidation reaction of compound **7**. <sup>d</sup> Calculated logarithm of the octanol/water distribution coefficient using JChem Version 14.9.100.707. <sup>e</sup> Compound not active.

Table 4

Activity of compounds selected for kinase selectivity and further cytotoxicity assessment.

ID	IC <sub>50</sub> , μM			EC <sub>50</sub> , μM	
	JAK2	JAK3	EGFR	Vero	A549
<b>5d</b>	>100	>100	>150	45.4	> 100
<b>5k</b>	0.126	4.1	>150	>100	4.2
<b>5m</b>	0.129	7.1	>100	37.0	9.4
<b>5n</b>	0.05	1.8	>150	2.0	3.5
<b>5o</b>	0.14	2.1	11.0	1.0	7.1

### 2.3.3. Protein kinase activity

Compounds **1a**, **5a-r** were evaluated for their *in vitro* inhibition of human kinases JAK2, JAK3 and EGFR (Table 4). Inhibition was determined by using an Antibody Beacon<sup>TM</sup> Tyrosine Kinase Assay Kit (A-35725; Invitrogen, USA). Compounds **5k,m-o** display sub μM inhibition at hJAK2 kinase, μM inhibition at hJAK3 and all compounds display >10 μM inhibition at hEGFR.

Compounds **5m** and **5o**, the most potent anti-malarials, but also the most cytotoxic of compounds are more active at the human kinases assessed. **5o** is a confirmed inhibitor of all three protein kinases while compound **5n** inhibits JAK2 at 0.05 μM. In contrast, **5d** shows minimal inhibition of the kinases and also displays good cytotoxicity at both the Vero and A549 cell lines.

Inhibiting multiple *Pf* kinase targets without harming human cells will be a challenge, particularly since many kinase compounds come from human anti-cancer projects.<sup>20</sup> Yet, there is considerable safety and tolerability information in relation to kinase inhibition profiles that could be leveraged to develop molecules with a more targeted pharmacology. Furthermore, tackling host-parasite target interactions is also a feature of established DHFR anti-malarials. Methotrexate, a hDHFR inhibitor used in cancer treatment, also has potential as a *Pf*DHFR anti-malarial if used at lower doses.<sup>51</sup>

## 3. Conclusions

We identified a series of diamino-pyrimidines anti-malarial from mining the screening data reported by GSK.<sup>26</sup> We performed the design, synthesis and testing of new analogs to reveal additional SAR with respect to the K1 strain, cytotoxicity at the Vero and A549 cell lines as well as inhibition at representative human kinases.

Sixteen new compounds have been synthesized and evaluated against the K1 resistant *Pf* strain. The compounds displayed activity comparable to chloroquine. We identified **5n** and **5o** as having sub μM anti-malarial activity. These compounds were also identified as being potent human kinase inhibitors as well as being cytotoxic. Compounds **5d** and **5k** were identified as μM inhibitors with improved cytotoxicity and human kinase selectivity.

Results suggest series has potential but further work needed to explore the strain dependence and maximize the anti-malarial/potency window. Additional work is required to establish the molecular target(s) of this compound class.

## 4.1. Chemistry

Reagents and solvents obtained from commercial suppliers were used without further purification. All reactions were monitored by TLC aluminum/silica gel plate with UV light visualization. Column chromatography was performed using silica gel 60 (40-63 μm). <sup>1</sup>H NMR spectra were recorded on both Varian instrument at 400 MHz and on a Bruker instrument at 500 MHz. Chemical shifts were reported in ppm (δ) using the residual solvent line as the internal standard. Mass spectra (MS) were performed on Agilent 1100 HPLC instrument coupled to a LC|MSD Trap mass spectrometer, in ESI(+) mode or APCI mode. Compounds showed a purity ≥ 95% as determined from the corresponding UV absorbance HPLC chromatogram.

### 4.2. Preparation of anilines 3a-c

#### 4.2.1. 3-methyl-4-(4-methylpiperazin-1-yl)aniline (3a)

A mixture of 1-fluoro-2-methyl-4-nitro-benzene (3.22 mmol), 1-methylpiperazine (3.63 mmol) and potassium carbonate (3.83 mmol) in dimethyl sulfoxide (4 ml) were stirred and heated to 100 °C for 4 hours. The resultant reaction solution was cooled down to room temperature, added water (50 ml) to the reaction mixture, filtered off the solid residue, washed with water (50 ml), and air-dried to give the desired product of 1-methyl-4-(2-methyl-4-nitrophenyl-piperazine (**2a**) as a brown solid, 77% yield. <sup>1</sup>H NMR (500 MHz, Chloroform-d) δ 8.04 (d, *J*=8.3 Hz, 2H), 7.01 (d, *J*=8.4 Hz, 1H), 3.07 (t, *J*=4.8 Hz, 4H), 2.67-2.57 (m, 4H), 2.39 (s, 3H), 2.37 (s, 3H). [M+H]<sup>+</sup>, ESI *m/z* 236.29. MW: 235.28 g/mol.

Afterwards, the obtained compound, **2a** was hydrogenated. Pd/C (2.78 mmol) was added to a stirred solution of 1-methyl-4-(2-methyl-4-nitrophenyl-piperazine (5.53 mmol) in methyl alcohol (15 ml) in N<sub>2</sub> atmosphere. Following this it was hydrogenated overnight by maintaining the reaction flask in an atmosphere of H<sub>2</sub> gas (balloon). The resultant was filtered thorough celite plate and concentrated under vacuum. The crude product was purified with silica-gel column chromatography (5%MeOH/DCM, 1%NH<sub>3</sub>) to yield the desired product, **3a** as a brown solid, 87% yield. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) δ 6.74 (d, *J*=8.4 Hz, 1H), 6.38 (d, *J*=2.7 Hz, 1H), 6.34 (dd, *J*=8.4, 2.7 Hz, 1H), 4.61 (s, 2H), 2.68 (t, *J*=4.8 Hz, 4H), 2.41 (s, 4H), 2.20 (s, 3H), 2.10 (2, 3H). [M+H]<sup>+</sup>, ESI *m/z* 206.23. MW: 205.30 g/mol.

#### 4.2.2. 4-(4-methylpiperazin-1-yl)aniline (3b)

A solution of 4-fluoronitrobenzene (7.1 mmol) and potassium carbonate (8.52 mol) in dimethyl sulfoxide (2 ml) was stirred at room temperature for 0.5 hour. 1-methylpiperazine (7.1 mmol) was added dropwise in the mixture solution. The resulting reaction mixture was stirred at room temperature for 6 hours. The mixture was then poured into cold water. A yellow precipitate formed and was collected to give 1-methyl-4-(4-nitrophenyl)piperazine (**2b**), 93% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.16 – 8.09 (m, 2H), 6.86 – 6.80 (m, 2H), 3.53 – 3.46 (m, 4H), 2.70 – 2.60 (m, 2H), 2.42 (s, 3H). [M+H]<sup>+</sup>, APCI *m/z* 222.1. MW: 221.26 g/mol.

Following this it was hydrogenated using the same procedure as compound **2a** to yield the desired product, **3b** as a brown solid, 100% yield. <sup>1</sup>H NMR (400 MHz, DMSO) δ 6.69 – 6.64 (m, 2H), 6.50 – 6.44 (m, 2H), 4.53 (s, 1H), 2.91 – 2.85 (m, 4H), 2.45 –

2.37 (m, 4H). methyl proton overlaps with the solvent peak. [M+H]<sup>+</sup>, APCI m/z 192.2. MW: 191.27 g/mol.

#### 4.2.3. 4-(morpholin-4-yl)aniline (**3c**)

A mixture of 1-bromo-4-nitrobenzene (5.0 mmol), morpholine (5.0 mol) and potassium carbonate (6.0 mmol) in dimethyl sulfoxide (2 ml) were stirred and heated to 100 °C for 7 hours. The resultant reaction solution was allowed to cool to room temperature. The mixture solution was extracted with EtOAc. The organic layer was collected, washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and dried under reduced pressure. The crude product was purified with silica-gel column chromatography (30% EtOAc/hexane) to give the desired product of 4-(4-nitrophenyl)morpholine, **2c** as a yellow solid, 47% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.18 – 8.09 (m, 2H), 6.86 – 6.79 (m, 2H), 3.88 – 3.82 (m, 4H), 3.39 – 3.31 (m, 4H).

Following this compound **2c** was hydrogenated using the same procedure as compound **2a** to yield the desired product, **3c** as a purple solid, 97% yield. <sup>1</sup>H NMR (400 MHz, DMSO) δ 6.70 – 6.65 (m, 2H), 6.51 – 6.47 (m, 2H), 4.57 (s, 2H), 3.71 – 3.65 (m, 4H), 2.91 – 2.84 (m, 4H). [M+H]<sup>+</sup>, APCI m/z 179.1. MW: 178.23 g/mol.

### 4.3. General procedure for the preparation of intermediate compounds **4a-e**

DIPEA (0.86 mmol) was added to the solution of 2,4-dichloropyrimidine-5-carbonitrile (0.57 mmol) in DMF (0.5 ml) and stirred at room temperature for 10 minutes. A solution of aminobenzene reagent corresponding to desired product (0.57 mmol) in DMF (0.5 ml) was added dropwise to the reaction mixture and stirred for 1 hour. The resultant was evaporated under vacuum and extracted with EtOAc. The organic layer was collected, washed with brine, dried over MgSO<sub>4</sub>, filtered, and dried under reduced pressure. **4c** was obtained from the reaction of **4b**, whereby substitution at the 2- position occurred.

#### 4.3.1. 2-[(2-chloro-5-cyano-pyrimidin-4-yl)amino]benzamide (**4a**)

2-aminobenzamide is used as an aminobenzene reagent, followed the general procedure and purified by silica-gel column chromatography (25%EtOAc/hexane) to yield **4a** as a yellow solid, yield 41%, <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>) δ 12.23 (s, 1H), 8.95 (s, 1H), 8.40 (d, *J* = 8.4 Hz, 1H), 8.31 (s, 1H), 7.84 (dd, *J* = 7.9, 1.5 Hz, 1H), 7.80 (s, 1H), 7.58 (t, *J* = 7.6 Hz, 1H), 7.21 (t, *J* = 7.6 Hz, 1H), MS-ESI: m/z 273.67 [M+H]<sup>+</sup>. MW: 273.68 g/mol.

#### 4.3.2. 3-[(2-chloro-5-cyano-pyrimidin-4-yl)amino]benzenesulfonamide (**4b**)

2-aminobenzensulfonamide is used as an aminobenzene reagent, followed the general procedure and purified by silica-gel column chromatography (10%EtOAc/hexane) to yield **4b** as a beige solid, yield 32%, <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>) δ 11.07 (s, 1H), 8.95 (s, 1H), 8.20 (s, 1H), 7.89 – 7.83 (m, 1H), 7.61 – 7.55 (m, 2H), 7.39 (s, 2H). MS-ESI: m/z 309.89 [M+H]<sup>+</sup>. MW: 309.73 g/mol.

#### 4.3.3. 3-[(4-chloro-5-cyano-pyrimidin-4-yl)amino]benzenesulfonamide (**4c**)

**4c** was obtained as a side product from the reaction of **4b**, whereby substitution at the 2-position occurred. Purified by silica-gel column chromatography (10%EtOAc/hexane), a beige solid, yield 35%, <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>) δ 10.56 (s, 1H), 8.79 (s, 1H), 7.99 (t, *J* = 1.8 Hz, 1H), 7.80 (ddd, *J* = 8.1, 2.2, 1.1 Hz, 1H), 7.67 (dt, *J* = 7.9, 1.4 Hz, 1H), 7.60 (t, *J* = 7.9 Hz, 1H), 7.40 (s, 2H). MS-ESI: m/z 310.06 [M+H]<sup>+</sup>. MW: 309.73 g/mol.

#### 4.3.4. 2-chloro-4-(3-methylsulfonylanilino)pyrimidine-5-carbonitrile (**4d**)

3-(methylsulfonyl)aniline hydrochloride is used as an aminobenzene reagent, followed the general procedure and purified by silica-gel column chromatography (5%MeOH/DCM) to yield **4d** as a yellow solid, yield 13%, <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>) δ 11.14 (s, 1H), 8.99 (s, 1H), 8.31 (s, 1H), 7.97 (dt, *J* = 6.4, 2.4 Hz, 1H), 7.69 – 7.62 (m, 2H), 3.21 (d, *J* = 1.4 Hz, 3H). MS-ESI: m/z 309.0 [M+H]<sup>+</sup>. MW: 308.74 g/mol.

#### 4.3.5. *N*-tert-butyl-3-[(2-chloro-5-cyano-pyrimidin-4-yl)benzenesulfonamide] (**4e**)

*N*-*t*-butyl-3-aminobenzensulfonamide is used as an aminobenzene reagent, followed the general procedure and purified by silica-gel column chromatography (0-5%MeOH/DCM) to yield **4e** as a beige solid, yield 30%, <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>) δ 11.06 (s, 1H), 8.94 (s, 1H), 8.21 (s, 1H), 7.85 – 7.81 (m, 1H), 7.56 (dd, *J* = 2.6, 1.4 Hz, 1H), 7.55 (d, *J* = 4.6 Hz, 2H), 1.12 (s, 9H). MS-ESI: m/z 366.08 [M+H]<sup>+</sup>. MW: 365.84 g/mol.

### 4.4. General procedure for the preparation of intermediate compounds **4f**

#### 4.4.1. 3-[(2-chloro-5-methoxypyrimidin-4-yl)amino]benzene-1-sulfonamide (**4f**)

3-aminobenzensulfonamide (3.07 mmol) and DIPEA (8.38 mmol) was added to the mixture of 2,4-dichloro-5-methoxypyrimidine (2.79 mmol) in 1,4-dioxane (15 ml). The reaction mixture was stirred at 100°C for 3 days. The solvent was evaporated under reduce pressure and extracted with EtOAc. The organic layer was collected, washed with brine, dried over MgSO<sub>4</sub>, filtered, and dried under reduced pressure. The crude product was purified with column chromatography (5% MeOH/DCM) to give the desired product, **4f** as a light yellow solid with a 22% yield, <sup>1</sup>H NMR (500MHz, DMSO-*d*<sub>6</sub>) δ 9.58 (s, 1H), 8.29-8.24 (m, 1H), 8.00 (s, 1H), 7.99-7.95 (m, 1H), 7.56-7.52 (m, 2H), 7.34 (s, 2H), 3.95 (s, 3H). MS-ESI: m/z 315.28 [M+H]<sup>+</sup>. MW: 314.75 g/mol.

### 4.5. General procedure for the preparation of compounds **4g-4i**

#### 4.5.1. 2-[(2-chloropyrimidin-4-yl)amino]benzamide (**4g**)

A mixture of 2,4-dichloropyrimidine and 2-aminobenzamide in 0.1M HCl was stirred at 100°C for 3 hrs. The precipitated obtained was filtered and the product was washed with water and recrystallized in methanol. The crystal product was collected and air-dried to give the desired intermediate compound, **4g** as a light green solid, with a 39% yield. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ 11.24 (s, 1H), 8.18 (dd, *J* = 11.3, 7.1 Hz, 3H), 7.76 (dd, *J* = 7.9, 1.5 Hz, 1H), 7.70 (s, 1H), 7.56 – 7.50 (m, 1H), 7.17 (td, *J* = 7.7, 1.1 Hz, 1H), 6.87 (d, *J* = 5.9 Hz, 1H). MS-APCI: m/z, 249.1 [M+H]<sup>+</sup>. MW: 248.67 g/mol.

#### 4.5.2. 3-[(2-chloropyrimidin-4-yl)amino]benzenesulfonamide (**4h**)

A solution of 2,4-dichloropyrimidine, 3-aminobenzenesulfonamide and DIPEA in n-BuOH was stirred at 110 °C for 13 hrs. The reaction mixture was cooled down to room temperature, concentrated under reduce pressure, and extracted with EtOAc. The organic layer was collected, washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and dried under reduced pressure. The crude product was purified with column chromatography (10% MeOH/DCM) to give the desired intermediate compound, **4h** as a beige solid, with a 48% yield. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ 10.31 (s, 1H), 8.23 (d, *J* = 5.9 Hz, 1H), 8.03 (d, *J* = 1.8 Hz, 1H), 7.90 (d, *J* = 7.9 Hz, 1H), 7.54 (tt, *J* = 4.6, 2.9 Hz, 2H), 6.80 (s, 1H). MS-APCI: m/z 285.1 [M+H]<sup>+</sup>. MW: 284.72 g/mol.

#### 4.5.3. 2-chloro-N-(3-methylphenyl)pyrimidin-4-amine (**4i**)

**4i** was prepared using the same procedure as **4h**, with a 25 hours of reaction time. A desired intermediate product **4i** was obtained as beige solid, with a 65% yield. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ 9.94 (s, 1H), 8.13 (dd, *J* = 5.8, 3.2 Hz, 1H), 7.40 (d, *J* = 7.8 Hz, 1H), 7.34 (s, 1H), 7.25 (t, *J* = 7.8 Hz, 1H), 6.92 (d, *J* = 7.3 Hz, 1H), 6.75 – 6.72 (m, 1H), 2.30 (s, 3H), MS-APCI: m/z 220.1 [M+H]<sup>+</sup>. MW: 219.67 g/mol.

### 4.6. General procedure for the synthesis of compound **1a**, **5a-d**

A chloro-intermediate compound (**4a-e**) (0.22 mmol) and DIPEA (0.33 mmol) were dissolved in DMF (0.5 ml). A solution of amino-intermediate compound (**3a-c**) (0.2 mmol) in DMF (0.5 ml) was then added dropwise into the solution. The reaction mixture was stirred at room temperature for 4 hours. The resultant solution was concentrated under vacuum, and extracted with EtOAc. The organic layer was collected, washed with brine, dried over MgSO<sub>4</sub>, filtered, and dried under reduced pressure.

#### 4.6.1. 2-[[5-cyano-2-[3-methyl-4-(4-methylpiperazin-1-yl)aniline]pyrimidin-4-yl]amino]benzamide (**1a**)

Compound **3a** as the amino-intermediate and **4a** as the chloro-intermediate, following the general procedure. Purified by silica-gel column chromatography (5%MeOH/DCM, 1%NH<sub>3</sub>) to give the desired product, **1a** with a 25% yield as a beige solid. <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>) δ 11.67 (s, 1H), 9.51 (s, 1H), 8.49 (s, 1H), 8.39 (d, *J* = 8.5 Hz, 1H), 8.20 (s, 1H), 7.74 (dd, *J* = 7.9, 1.5 Hz, 1H), 7.69 (s, 1H), 7.33 (d, *J* = 2.5 Hz, 1H), 7.29 – 7.24 (m, 1H), 7.20 (t, *J* = 8.0 Hz, 1H), 7.03 (dd, *J* = 16.6, 8.2 Hz, 2H), 2.87 (t, *J* = 4.7 Hz, 4H), 2.25 (s, 3H), 2.24 (s, 3H). MS-ESI: m/z 443.13 [M+H]<sup>+</sup>. MW: 442.53 g/mol.

#### 4.6.2. 3-[[5-cyano-2-[3-methyl-4-(4-methylpiperazin-1-yl)aniline]pyrimidin-4-yl]amino]benzenesulfonamide (**5a**)

Compound **3a** as the amino-intermediate and **4b** as the chloro-intermediate, following the general procedure. Purified by silica-gel column chromatography (5%MeOH/DCM, 1%NH<sub>3</sub>), a beige solid, yield 23%. <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>) δ 10.07 (s, 1H), 9.38 (s, 1H), 8.50 (d, *J* = 1.3 Hz, 1H), 7.99 (d, *J* = 8.1 Hz, 1H), 7.90 (s, 1H), 7.45 – 7.40 (m, 1H), 7.31 (s, 3H), 7.27 (s, 2H), 7.02 (d, *J* = 8.2 Hz, 1H), 2.85 (t, *J* = 4.7 Hz, 4H), 2.25 (s, 3H), 2.23 (s, 3H). MS-ESI: m/z 479.20 [M+H]<sup>+</sup>. MW: 478.58 g/mol.

#### 4.6.3. 3-[[5-cyano-4-[3-methyl-4-(4-methylpiperazin-1-yl)aniline]pyrimidin-2-yl]amino]benzenesulfonamide (**5b**)

Compound **3a** as the amino-intermediate and **4c** as the chloro-intermediate, following the general procedure. Purified by silica-gel column chromatography (5%MeOH/DCM, 1%NH<sub>3</sub>), a beige solid, yield 15%. <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>) δ 9.67 (s, 1H), 8.48 (s, 1H), 8.35 (d, *J* = 2.5 Hz, 1H), 7.71 (dt, *J* = 6.6, 2.3 Hz, 1H), 7.51 (dd, *J* = 5.0, 2.8 Hz, 2H), 7.30 (d, *J* = 7.0 Hz, 2H), 6.74 (d, *J* = 8.4 Hz, 1H), 6.41 (d, *J* = 2.4 Hz, 1H), 6.34 (dd, *J* = 8.5, 2.6 Hz, 1H), 4.66 (s, 2H), 2.72 (d, *J* = 5.4 Hz, 4H), 2.16 (s, 3H). MS-ESI: m/z 479.12 [M+H]<sup>+</sup>. MW: 478.58 g/mol.

#### 4.6.4. 2-[3-methyl-4-(4-methylpiperazin-1-yl)aniline]-4-(3-methylsulfonylanilino)pyrimidine-5-carbonitrile (**5c**)

Compound **3a** as the amino-intermediate and **4d** as the chloro-intermediate, following the general procedure. Purified by silica-gel column chromatography (0-10%MeOH/DCM, 1%NH<sub>3</sub>), a yellow solid, yield 26%. <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>) δ 10.12 (s, 1H), 9.42 (s, 1H), 8.52 (s, 1H), 8.10 (dd, *J* = 8.0, 2.1 Hz, 1H), 7.98 (s, 1H), 7.50 (dt, *J* = 7.8, 1.3 Hz, 1H), 7.37 (s, 1H), 7.30 (d, *J* = 11.7 Hz, 2H), 7.02 (d, *J* = 8.4 Hz, 1H), 3.11 (s, 3H), 2.85 (t, *J* = 4.6 Hz, 4H), 2.24 (s, 4H), 2.22 (s, 3H), 1.98 (s, 1H). MS-ESI: m/z 478.25 [M+H]<sup>+</sup>. MW: 477.59 g/mol.

#### 4.6.5. N-tert-butyl-3-(5-cyano-2-(3-methyl-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-ylamino)benzene-sulfonamide (**5d**)

Compound **3a** as the amino-intermediate and **4e** as the chloro-intermediate, following the general procedure. Purified by silica-gel column chromatography (5%MeOH/DCM, 1%NH<sub>3</sub>), a beige solid, yield 39%. <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>) δ 10.06 (s, 1H), 9.38 (s, 1H), 8.49 (s, 1H), 8.00 (d, *J* = 8.2 Hz, 1H), 7.90 (s, 1H), 7.44 – 7.40 (m, 2H), 7.29 (d, *J* = 16.0 Hz, 3H), 7.02 (d, *J* = 8.5 Hz, 1H), 2.85 (t, *J* = 4.7 Hz, 4H), 2.25 (s, 3H), 2.22 (s, 3H), 1.09 (s, 9H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 164.71, 162.44, 160.56, 159.89, 158.68, 147.38, 144.62, 139.53, 133.06, 132.33, 122.64, 119.88, 119.15, 118.21, 117.79, 116.86, 116.39, 53.00, 50.92, 46.34, 35.66, 29.88, 21.80, 17.43, 13.93. MS-ESI: m/z 535.24 [M+H]<sup>+</sup>. MW: 534.68 g/mol.

### 4.7. General procedure for the synthesis of compound **5e-g**

#### 4.7.1. 2,4-bis(3-methylanilino)pyrimidine-5-carbonitrile (**5e**)

3-methylaniline (0.29 mmol) and DIPEA were added to a solution of 2,4-dichloropyrimidine-5-carbonitrile (0.29 mmol) in DMF (5 ml). The reaction mixture was stirred at room temperature for 4.5 hrs. The reaction mixture was then extracted with EtOAc. The organic layer was collected, washed with brine, dried over MgSO<sub>4</sub>, filtered, and dried under reduced pressure to yield the desired product, **5e** which disubstituted reaction at 2- and 4-position occurred, with a 50% yield as a white solid. <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>) δ 9.80 (s, 1H), 9.40 (s, 1H), 8.48 (s, 1H), 7.40 (s, 1H), 7.36 (q, *J* = 18.1, 10.4 Hz, 4H), 7.30 (t, *J* = 8.1 Hz, 1H), 7.24 (t, *J* = 8.0 Hz, 1H), 7.09 (d, *J* = 7.6 Hz, 1H), 7.03 (d, *J* = 4.9 Hz, 3H), 6.99 (d, *J* = 7.7 Hz, 1H), 6.78 (d, *J* = 7.4 Hz, 1H), 2.28 (s, 3H), 2.14 (s, 3H). MS-ESI: m/z 316.31 [M+H]<sup>+</sup>. MW: 315.38 g/mol.

#### 4.7.2. 2,4-bis(3-methylanilino)pyrimidine-5-carboxamide (**5f**)

**5e** (0.09 mmol), hydrogen peroxide solution (0.86 mmol) and 1M NaOH (0.17 mmol) in methyl alcohol (1 ml) were stirred to 40°C for 24 hrs. The reaction mixture was concentrated under

vacuum and extracted with EtOAc. The organic layer was collected, washed with brine, dried over MgSO<sub>4</sub>, filtered, and dried under reduced pressure. The crude product was purified by column chromatography (0-10% MeOH/DCM, 1% NH<sub>3</sub>) to give **5f**, with a 48% yield as a beige solid. <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>) δ 11.52 (s, 1H), 9.55 (s, 1H), 8.69 (s, 1H), 7.99 (s, 1H), 7.51 (s, 2H), 7.47 (dd, *J* = 8.4, 2.1 Hz, 1H), 7.40 (s, 1H), 7.21 (t, *J* = 7.8 Hz, 1H), 7.13 (t, *J* = 7.8 Hz, 1H), 6.90 (dd, *J* = 7.4, 1.7 Hz, 1H), 6.83 – 6.79 (m, 1H), 2.27 (s, 3H), 2.22 (s, 3H). MS-ESI: *m/z* 334.13 [M+H]<sup>+</sup>. 333.40 g/mol.

#### 4.7.3. 3-[2-methoxy-5-[3-methyl-4-(4-methylpiperazin-1-yl)aniline]aniline]benzenesulfonylamide (**5g**)

Compound **3a** was dissolved in tetrahydrofuran (0.4 ml) and treated with a solution of 1M HCl (0.33 mmol) in ethyl ether. The mixture was stirred for 15 minutes and then concentrated under vacuum. The residue was then treated with **4f** (0.16 mmol) and 2-propanol (0.8 ml). The suspension was stirred at 100°C for 5 days. The reaction mixture was added to a NaHCO<sub>3</sub> solution (10 ml) and extracted with EtOAc. The organic layer was collected, washed with brine, dried over MgSO<sub>4</sub>, filtered, and dried under reduced pressure to give the desired product, **5g** with a 91% yield as a beige solid. <sup>1</sup>H NMR (500 MHz, Methanol-*d*<sub>4</sub>) δ 8.32 (t, *J* = 2.0 Hz, 1H), 8.04 (ddd, *J* = 8.2, 2.2, 1.0 Hz, 1H), 7.71 (s, 1H), 7.58 (dt, *J* = 7.9, 1.3 Hz, 1H), 7.46 (t, *J* = 8.0 Hz, 1H), 7.33-7.35 (m, 2H), 7.01 (d, *J* = 8.2 Hz, 1H), 3.92 (s, 3H), 2.96 (t, *J* = 4.9 Hz, 4H), 2.76 (s, 4H), 2.46 (s, 3H), 2.26 (s, 3H). MS-ESI: *m/z* 484.23 [M+H]<sup>+</sup>. MW: 483.59 g/mol.

### 4.8. General procedure for the synthesis of compounds **5h-5r**

A chloro-intermediate (**4g-i**) (0.32 mmol) and amino-intermediate (**3a-c**) (0.32 mmol) were combined in a round bottom flask with 5 ml of isopropanol and catalytic amounts of TFA. The reaction mixture was stirred at 80°C overnight. The reaction was then cooled down to room temperature, neutralized with 1 M NaOH, and evaporated under vacuum to give a crude product. The crude product was purified by silica-gel column chromatography to yield a desired product.

#### 4.8.1. 2-[(2-[[3-methyl-4-(4-methylpiperazin-1-yl)phenyl]amino]pyrimidin-4-yl)amino]benzamide (**5h**)

Compound **3a** as the amino-intermediate and **4g** as the chloro-intermediate, following the general procedure. Purified by silica-gel column chromatography (5-10% MeOH/DCM, 1% NH<sub>3</sub>), a beige solid, yield 67%, <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ 11.10 (s, 1H), 9.05 (s, 1H), 8.57 (d, *J* = 8.3 Hz, 1H), 8.21 (s, 1H), 8.04 (d, *J* = 5.7 Hz, 1H), 7.77 – 7.73 (m, 1H), 7.66 (s, 1H), 7.52 (d, *J* = 2.3 Hz, 1H), 7.46 – 7.37 (m, 2H), 7.04 (t, *J* = 7.0 Hz, 1H), 6.93 (s, 1H), 6.20 (d, *J* = 5.7 Hz, 1H), 2.80 (t, *J* = 4.6 Hz, 4H), 2.23 (s, 3H), 2.20 (s, 3H). Another set of 4 protons is overlapped under water peak. MS-APCI: *m/z*, 418.3 [M+H]<sup>+</sup>. MW: 417.52 g/mol.

#### 4.8.2. 2-[(2-[[4-(4-methylpiperazin-1-yl)phenyl]amino]pyrimidin-4-yl)amino]benzamide (**5i**)

Compound **3b** as the amino-intermediate and **4g** as the chloro-intermediate, following the general procedure. Purified by silica-gel column chromatography (5% MeOH/DCM, 1% NH<sub>3</sub>), a brown solid, yield 56%, <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ 11.07 (s, 1H), 8.99 (s, 1H), 8.57 (d, *J* = 8.5 Hz, 1H), 8.20 (s, 1H), 8.01 (t, *J* = 5.2 Hz, 1H), 7.76 (dd, *J* = 7.9, 1.5 Hz, 1H), 7.65 (s, 1H), 7.52 (d, *J* = 9.0 Hz, 2H), 7.44 (dd, *J* = 11.4, 4.3 Hz, 1H), 7.03 (dd, *J* =

11.1, 4.1 Hz, 1H), 6.87 (d, *J* = 9.1 Hz, 2H), 6.17 (d, *J* = 5.7 Hz, 1H), 3.09 – 3.03 (m, 4H), 2.48 – 2.44 (m, 4H), 2.22 (s, 3H). MS-APCI: *m/z*, 404.3 [M+H]<sup>+</sup>. MW: 403.49 g/mol.

#### 4.8.3. 2-[(2-[[4-(morpholin-4-yl)phenyl]amino]pyrimidin-4-yl)amino]benzamide (**5j**)

Compound **3c** as the amino-intermediate and **4g** as the chloro-intermediate, following the general procedure. Purified by silica-gel column chromatography (5% MeOH/DCM, 1% NH<sub>3</sub>), a white solid, yield 11%, <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ 11.08 (s, 1H), 9.02 (s, 1H), 8.57 (d, *J* = 8.4 Hz, 1H), 8.21 (s, 1H), 8.03 (d, *J* = 5.7 Hz, 1H), 7.76 (d, *J* = 7.8 Hz, 1H), 7.66 (s, 1H), 7.54 (d, *J* = 9.0 Hz, 2H), 7.45 (t, *J* = 7.1 Hz, 1H), 7.04 (t, *J* = 7.6 Hz, 1H), 6.88 (d, *J* = 9.0 Hz, 2H), 6.18 (d, *J* = 5.7 Hz, 1H), 3.78 – 3.72 (m, 4H), 3.07 – 3.01 (m, 4H), MS-APCI: *m/z*, 391.3 [M+H]<sup>+</sup>. MW: 390.45 g/mol.

#### 4.8.4. 3-[(2-[[3-methyl-4-(4-methylpiperazin-1-yl)phenyl]amino]pyrimidin-4-yl)amino]benzene-1-sulfonamide (**5k**)

Compound **3a** as the amino-intermediate and **4h** as the chloro-intermediate, following the general procedure. Purified by silica-gel column chromatography (5% MeOH/DCM, 1% NH<sub>3</sub>), a brown solid, yield 70%, <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ 9.63 (s, 1H), 8.94 (s, 1H), 8.25 (d, *J* = 8.3 Hz, 1H), 8.03 (d, *J* = 5.7 Hz, 1H), 7.89 (s, 1H), 7.45 (ddd, *J* = 7.7, 7.2, 1.5 Hz, 4H), 7.37 (s, 2H), 6.95 (d, *J* = 8.7 Hz, 1H), 6.21 (d, *J* = 5.7 Hz, 1H), 2.80 (t, *J* = 4.5 Hz, 4H), 2.24 (s, 3H), 2.20 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-*d*<sub>6</sub>) δ 160.27, 159.58, 156.38, 145.46, 144.50, 140.64, 135.80, 131.82, 129.41, 122.46, 122.02, 118.84, 118.58, 117.85, 116.19, 98.65, 55.25, 51.56, 45.81, 40.19, 40.15, 39.98, 39.94, 39.73, 39.52, 39.31, 39.10, 38.89, 17.65. MS-APCI: *m/z* 454.2 [M+H]<sup>+</sup>. MW: 453.57 g/mol.

#### 4.8.5. 3-[(2-[[4-(4-methylpiperazin-1-yl)phenyl]amino]pyrimidin-4-yl)amino]benzene-1-sulfonamide (**5l**)

Compound **3b** as the amino-intermediate and **4h** as the chloro-intermediate, following the general procedure. Purified by silica-gel column chromatography (10% MeOH/DCM, 1% NH<sub>3</sub>), a beige solid, yield 62%, <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ 9.60 (s, 1H), 8.89 (s, 1H), 8.19 (d, *J* = 8.3 Hz, 1H), 8.01 (d, *J* = 5.7 Hz, 1H), 7.93 (s, 1H), 7.52 (d, *J* = 9.0 Hz, 2H), 7.44 (ddd, *J* = 11.1, 7.9, 4.7 Hz, 2H), 7.37 (s, 1H), 6.88 (d, *J* = 9.1 Hz, 1H), 6.18 (d, *J* = 5.7 Hz, 1H), 3.07 (t, *J* = 3.2 Hz, 3H), 2.26 (s, 3H). MS-APCI: *m/z* 440.2 [M+H]<sup>+</sup>. MW: 439.54 g/mol.

#### 4.8.6. 3-[(2-[[4-(morpholin-4-yl)phenyl]amino]pyrimidin-4-yl)amino]benzene-1-sulfonamide (**5m**)

Compound **3c** as the amino-intermediate and **4h** as the chloro-intermediate, following the general procedure. Purified by silica-gel column chromatography (5-10% MeOH/DCM, 1% NH<sub>3</sub>), a purple solid, yield 75%, <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ 9.62 (s, 1H), 8.92 (s, 1H), 8.18 (d, *J* = 8.5 Hz, 1H), 8.01 (d, *J* = 5.7 Hz, 1H), 7.93 (s, 1H), 7.53 (d, *J* = 9.0 Hz, 2H), 7.47 (t, *J* = 7.8 Hz, 1H), 7.42 (dt, *J* = 7.8, 1.4 Hz, 1H), 7.37 (s, 2H), 6.88 (d, *J* = 9.1 Hz, 2H), 6.19 (d, *J* = 5.7 Hz, 1H), 3.77 – 3.68 (m, 4H), 3.06 – 2.99 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-*d*<sub>6</sub>) δ 160.29, 159.69, 156.38, 146.10, 144.48, 140.64, 133.05, 129.37, 122.57, 120.76, 118.59, 116.18, 115.62, 98.46, 66.20, 49.35, 40.19, 40.15, 39.98, 39.94, 39.73, 39.52, 39.31, 39.10, 38.89. MS-APCI: *m/z* 427.2 [M+H]<sup>+</sup>. MW: 426.50 g/mol.

4.8.7. 2-*N*-[4-(3,4-dimethylpiperazin-1-yl)phenyl]-4-*N*-(3-methylphenyl)pyrimidine-2,4-diamine (**5n**) (m, 4H), 3.06 – 2.99 (m, 4H), MS-APCI: m/z, 434.3 [M+H]<sup>+</sup>. MW: 432.53 g/mol.

Compound **3a** as the amino-intermediate and **4i** as the chloro-intermediate, following the general procedure. Purified by silica-gel column chromatography (5% MeOH/DCM, 1% NH<sub>3</sub>), a brown solid, yield 80%, <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ 9.20 (s, 1H), 8.90 (s, 1H), 7.96 (d, *J* = 5.7 Hz, 1H), 7.48 (dd, *J* = 15.8, 8.0 Hz, 4H), 7.16 (t, *J* = 7.8 Hz, 1H), 6.92 (d, *J* = 8.5 Hz, 1H), 6.80 (d, *J* = 7.5 Hz, 1H), 6.15 (d, *J* = 5.7 Hz, 1H), 2.78 (d, *J* = 4.3 Hz, 4H), 2.27 (s, 3H), 2.23 (s, 3H), 2.18 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-*d*<sub>6</sub>) δ 160.44, 159.71, 155.99, 145.29, 140.07, 137.77, 136.01, 131.78, 128.48, 122.65, 122.01, 120.26, 118.72, 117.79, 116.96, 98.28, 55.28, 51.63, 45.87, 40.20, 40.15, 39.99, 39.94, 39.73, 39.52, 39.31, 39.10, 38.89, 21.23, 17.58. MS-APCI: m/z 389.4 [M+H]<sup>+</sup>. MW: 388.52 g/mol.

4.8.8. 4-*N*-(3-methylphenyl)-2-*N*-[4-(4-methylpiperazin-1-yl)phenyl]pyrimidine-2,4-diamine (**5o**)

Compound **3b** as the amino-intermediate and **4i** as the chloro-intermediate, following the general procedure. Purified by silica-gel column chromatography (5% MeOH/DCM, 1% NH<sub>3</sub>), a yellow solid, yield 82%, <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ 9.18 (s, 1H), 8.85 (s, 1H), 7.94 (d, *J* = 5.7 Hz, 1H), 7.59 – 7.47 (m, 3H), 7.43 (d, *J* = 6.6 Hz, 1H), 7.16 (t, *J* = 7.7 Hz, 1H), 6.85 (d, *J* = 8.9 Hz, 2H), 6.79 (d, *J* = 7.1 Hz, 1H), 6.13 (d, *J* = 5.7 Hz, 1H), 3.04 (t, *J* = 2.8 Hz, 4H), 2.46 (t, *J* = 4.4 Hz, 4H), 2.27 (s, 3H), 2.22 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-*d*<sub>6</sub>) δ 160.45, 159.85, 155.99, 145.97, 140.11, 137.77, 132.96, 128.43, 122.57, 120.79, 120.19, 116.89, 115.84, 98.03, 54.73, 48.98, 45.79, 40.19, 40.15, 39.98, 39.94, 39.77, 39.73, 39.52, 39.31, 39.10, 38.89, 21.31. MS-APCI: m/z 375.3 [M+H]<sup>+</sup>. MW: 374.49 g/mol.

4.8.9. 4-*N*-(3-methylphenyl)-2-*N*-[4-(morpholin-4-yl)phenyl]pyrimidine-2,4-diamine (**5p**)

Compound **3c** as the amino-intermediate and **4i** as the chloro-intermediate, following the general procedure. Purified by silica-gel column chromatography (5% MeOH/DCM, 1% NH<sub>3</sub>), a brown solid, yield 78%, <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ 9.18 (s, 1H), 8.88 (s, 1H), 7.95 (d, *J* = 5.7 Hz, 1H), 7.58 – 7.51 (m, 3H), 7.44 (d, *J* = 8.1 Hz, 1H), 7.16 (dd, *J* = 10.1, 5.5 Hz, 1H), 6.88 – 6.83 (m, 2H), 6.80 (d, *J* = 7.5 Hz, 1H), 6.14 (d, *J* = 5.7 Hz, 1H), 3.78 – 3.69 (m, 4H), 3.05 – 2.97 (m, 4H). MS-APCI: m/z 362.3 [M+H]<sup>+</sup>. MW: 361.45 g/mol.

4.8.10. *N,N'*-bis(3-methylphenyl)pyrimidine-2,4-diamine (**5q**)

**5q** was a by-product obtained from the double substitution reaction from the aniline used to produce **4i**. Purified by silica-gel column chromatography (10% MeOH/DCM), a beige solid, yield 2%, <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ 9.25 (s, 1H), 9.05 (s, 1H), 7.99 (d, *J* = 5.7 Hz, 1H), 7.53 (d, *J* = 7.1 Hz, 3H), 7.46 (s, 1H), 7.18 (t, *J* = 7.8 Hz, 1H), 7.14 – 7.07 (m, 1H), 6.82 (d, *J* = 7.5 Hz, 1H), 6.73 (d, *J* = 7.4 Hz, 1H), 6.20 (d, *J* = 5.7 Hz, 1H), 2.28 (s, 3H), 2.24 (s, 3H), MS-APCI: m/z 291.2 [M+H]<sup>+</sup>. MW: 290.37 g/mol.

4.8.11. 2-*N*,4-*N*-bis[4-(morpholin-4-yl)phenyl]pyrimidine-2,4-diamine (**5r**)

**5r** was a by-product from the elimination of 2-aminobenzamide on the 2-position of compound **5j**. Purified by silica-gel column chromatography (5% MeOH/DCM, 1% NH<sub>3</sub>), a yellow solid, yield 20%, <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ 10.13 (s, 1H), 9.02 (s, 1H), 8.51 (d, *J* = 8.9 Hz, 1H), 8.06 (d, *J* = 5.6 Hz, 1H), 7.94 (dd, *J* = 8.0, 1.6 Hz, 1H), 7.60 – 7.49 (m, 3H), 7.15 – 7.08 (m, 1H), 6.86 (d, *J* = 9.1 Hz, 2H), 6.26 (d, *J* = 5.7 Hz, 1H), 3.76 – 3.71

## 4.9. Biological Assays

### 4.9.1. Anti-Malarial Activity

Multidrug resistant *Plasmodium falciparum* (K1 strain) were cultivated as previously described.<sup>43,52</sup> Briefly, *P. falciparum* were cultivated in RPMI-1640 medium supplement with 25 mM HEPES, 25 mM NaHCO<sub>3</sub>, 10% heat-activated human serum and 3% erythrocytes. The culture is incubated at 37°C in a humidified incubator with 3% CO<sub>2</sub> and daily passaged to fresh medium containing erythrocyte to maintain parasite growth. The *in vitro* antimalarial activity of the test peptides were tested against multidrug resistant *Plasmodium falciparum* (K1 strain) using a semi-automated microdilution technique.<sup>42</sup> 200 μl of early ring state parasite mixture (1% parasitemia, 1.5% Hct) were added into each well of a 96 well plate. Then, 25 μl tested peptide were added in duplicate. Plates were incubated in CO<sub>2</sub> incubator for 24 hours, then 25 μl of medium containing 0.5 μCi [<sup>3</sup>H] hypoxanthine (Perkin Elmer, USA) were added and incubated for 18-20 hours. The levels of incorporated radioactive labeled hypoxanthine, indicating parasite growth, were determined by using the TopCount microplate scintillation counter (Packard, USA). Dihydroartemisinin chloroquine and mefloquine were used as positive control and 0.5% DMSO was used as negative controls. The antimalarial activity was expressed as the inhibitory concentration (IC<sub>50</sub>), representing the concentration of drug that reduced 50% of parasite growth. Data fitting was performed using SOFTMax Pro (Molecular Devices, USA).

### 4.9.2. Cytotoxicity

The percent cytotoxicity against the Vero cell line (ATCC CCL-81) at 10 μM employed the method described by Hunt and co-workers.<sup>44</sup> The GFP-expressing Vero cell line was generated by stably transfecting the Vero cells with pEGFP-N1 plasmid (Clontech) and maintained in minimal essential medium supplemented with 10% heat inactivated fetal bovine serum, 2 mM L-glutamine, 1 mM sodium pyruvate, 1.5 g/L sodium bicarbonate, and 0.8 mg/mL geneticin at 37°C in an incubator with 5% CO<sub>2</sub>. Vero cell suspension (45 μL, 3.3 × 10<sup>4</sup> cells/mL) was added into each well of 384-well plates containing 5 μL of test compounds. Plates were incubated in a CO<sub>2</sub> incubator at 37 °C for 4 days. Fluorescence signals were measured using SpectraMax M5 microplate reader (Molecular Devices, U.S.A.). Fluorescence signals were measured using SpectraMax M5 microplate reader (Molecular devices, U.S.A.) in the bottom-reading mode at the excitation and emission wavelengths of 530 and 590 nm. Ellipticine was used as the positive control and 0.5% DMSO as the negative control.

Dose response curves for a subset of compounds were determined in Vero (ATCC CCL-81) and A549 (ATCC CCL-185) cells. The MTT based method described by Mosman et al was employed.<sup>45</sup> Cells were cultured in DMEM medium with 10% fetal bovine serum, 100 U/ml penicillin, and 100 U/ml streptomycin at 37°C in a humidified atmosphere with 5% CO<sub>2</sub>. The cells were cultured in complete DMEM for 16-18 h, then cultured with compound for 72h. Each well was charged with DMEM containing 3-[4,5-dimethyl-2-thiazolyl]-2,5-diphenyl-2H-tetrazolium bromide (MTT) (5 mg/ml in normal sodium), and then cells were incubated for 3 h. The medium was carefully decanted and 50 μl of dimethyl sulfoxide was added. The plate was shaken mechanically for 5 min, and then absorbance readings at a wavelength of 570 nm were performed on a Sunrise

microplate reader (Tecan). Gefitinib was used as the positive control and 0.5% DMSO as the negative control.

#### 4.9.3. Protein kinase activity

All kinase assays were constituted and performed in a similar manner except for the following differences in reagents: For JAK2 kinase assays, the reaction contained 10ng JAK2 enzyme, 0.1 mg/ml poly (Glu:Tyr) substrate and 0.1 mg/ml ATP. For JAK3 kinase assays, the reaction contained 3ng JAK3 enzyme, 0.1 mg/ml poly (Glu:Tyr) substrate and 0.1 mg/ml ATP.

Inhibition was determined by using Antibody Beacon™ Tyrosine Kinase Assay Kit (A-35725; Invitrogen, USA). For the EGFR kinase assay, the detection complex contained the following components in 1X kinase assay buffer (50 mM Tris-HCl pH 7.5, 10 mM MgCl<sub>2</sub>, 1 mM EGTA, 0.01% Brig and 2mM DTT), 0.0267 mg/ml poly (Glu:Tyr), 6.7 nM anti-phosphotyrosine antibody, 0.33 nM Oregon Green 488 ligand and 0.5 mM ATP. To the reaction was added with 12.5 µl of test compounds and 12.5 µl of EGFR enzyme (3ng enzyme/ reaction). After that, 25 µl of the detection complex was added into each well. The mixture solution was analyzed for 1½ hour at 30°C in a fluorescence microplate reader using excitation at 485 nm and emission at 535 nm using an Infinite F200 fluorescence microplate reader (Tecan). The IC<sub>50</sub> data was obtained by fitting using Prism 6.0 (GraphPad Software Inc., San Diego, CA, USA). Erlotinib (EGFR) and compound-7c<sup>53</sup> (JAK2/3) were used as the positive control and 0.5% DMSO as the negative control.

## 5. Acknowledgments

The authors are grateful for financial support provided by the Faculty of Science at Kasetsart University (RFG1-5). MPG also acknowledges support from the Kasetsart University Research and Development Institute (KURDI) and the Thailand Research Fund (TRF, RSA570080). OP would like to acknowledge a scholarship provided by the Development and Promotion of Science and Technology Talents Project Grant (DPST). MPG and OP would like to thank Prof. S. Ruchirawat and Dr P. Ploypradith for discussions and technical assistance.

## 6. References and notes

- (1) Miller, L. H.; Ackerman, H. C.; Su, X.-z.; Wellems, T. E. *Nat Med* **2013**, *19*, 156.
- (2) Wu, T.; Nagle, A.; Chatterjee, A. *Curr Med Chem* **2011**, *18*, 853
- (3) WHO *World Malaria Report 2015*: <http://www.who.int/malaria/publications/world-malaria-report-2015/report/en/>; Geneva: World Health Organization, 2015.
- (4) Biamonte, M. A.; Wanner, J.; Le Roch, K. G. *Bioorganic & Medicinal Chemistry Letters* **2013**, *23*, 2829.
- (5) Sibley, C. H. *Science* **2015**, *347*, 373.
- (6) Ashley, E. A.; Dhorda, M.; Fairhurst, R. M.; Amaratunga, C.; Lim, P.; Suon, S.; Sreng, S.; Anderson, J. M.; Mao, S.; Sam, B.; Sopha, C.; Chuor, C. M.; Nguon, C.; Sovannaroth, S.; Pukrittayakamee, S.; Jittamala, P.; Chotivanich, K.; Chutasmit, K.; Suchatsoonthorn, C.; Runcharoen, R.; Hien, T. T.; Thuy-Nhien, N. T.; Thanh, N. V.; Phu, N. H.; Htut, Y.; Han, K.-T.; Aye, K. H.; Mokuolu, O. A.; Olaosebikan, R. R.; Folaranmi, O. O.; Mayxay, M.; Khanthavong, M.; Hongvanthong, B.; Newton, P. N.; Onyamboko, M. A.; Fanello, C. I.; Tshefu, A. K.; Mishra, N.; Valecha, N.; Phyto, A. P.; Nosten, F.; Yi, P.; Tripura, R.; Borrmann, S.; Bashraheil, M.; Peshu, J.; Faiz, M. A.; Ghose, A.; Hossain, M. A.; Samad, R.; Rahman, M. R.; Hasan, M. M.; Islam, A.; Miotto, O.; Amato, R.; MacInnis, B.; Stalker, J.; Kwiatkowski, D. P.; Bozdech, Z.; Jeeyapant, A.; Cheah, P. Y.; Sakulthaew, T.; Chalk, J.; Intharabut, B.; Silamut, K.; Lee, S. J.; Vihokhern, B.; Kunasol, C.; Imwong, M.; Tarning, J.; Taylor, W. J.; Yeung, S.; Woodrow, C. J.; Flegg, J. A.; Das, D.; Smith, J.; Venkatesan, M.; Plowe, C. V.; Stepniewska, K.; Guerin, P. J.; Dondorp, A. M.; Day, N. P.; White, N. J. *New England Journal of Medicine* **2014**, *371*, 411.
- (7) Barnett, D. S.; Guy, R. K. *Chemical Reviews* **2014**, *114*, 11221.
- (8) Wells, T. N. C.; van Huijsduijnen, R. H.; Van Voorhis, W. C. *Nat Rev Drug Discov* **2015**, *14*, 424.
- (9) Vial, H.; Taramelli, D.; Boulton, I. C.; Ward, S. A.; Doerig, C.; Chibale, K. *Malaria Journal* **2013**, *12*, 396.
- (10) Derbyshire, E. R.; Zuzarte-Luís, V.; Magalhães, A. D.; Kato, N.; Sanschagrin, P. C.; Wang, J.; Zhou, W.; Miduturu, C. V.; Mazitschek, R.; Sliz, P.; Mota, M. M.; Gray, N. S.; Clardy, J. *ChemBioChem* **2014**, *15*, 1920.
- (11) Lucet, I. S.; Tobin, A.; Drewry, D.; Wilks, A. F.; Doerig, C. *Future Medicinal Chemistry* **2012**, *4*, 2295.
- (12) Leroy, D.; Doerig, C. *Trends Pharmacol. Sci.* **2008**, *29*, 241.
- (13) Morahan, B.; Garcia-Bustos, J. *Molecular and Biochemical Parasitology* **2014**, *193*, 23.
- (14) Mbengue, A.; Bhattacharjee, S.; Pandharkar, T.; Liu, H.; Estiu, G.; Stahelin, R. V.; Rizk, S. S.; Njimoh, D. L.; Ryan, Y.; Chotivanich, K.; Nguon, C.; Ghorbal, M.; Lopez-Rubio, J.-J.; Pfender, M.; Emrich, S.; Mohandas, N.; Dondorp, A. M.; Wiest, O.; Haldar, K. *Nature* **2015**, *520*, 683.
- (15) Ghidelli-Disse, S.; Lafuente-Monasterio, M. J.; Waterson, D.; Witty, M.; Younis, Y.; Paquet, T.; Street, L. J.; Chibale, K.; Gamo-Benito, F. J.; Bantscheff, M.; Drewes, G. *Malaria Journal* **2014**, *13*, 1.
- (16) Jirage, D.; Keenan, S. M.; Waters, N. C. *Infect Disord Drug Targets*. **2010**, *10*, 134.
- (17) Doerig, C.; Meijer, L. *Expert Opin Ther Targets*. **2007**, *11*, 279.
- (18) Zhang, V.; Chavchich, M.; Waters, N. *Curr Top Med Chem* **2012**, *12*, 456
- (19) Ward, P.; Equinet, L.; Packer, J.; Doerig, C. *BMC Genomics* **2004**, *5*, 79.
- (20) Crowther, G. J.; Hillesland, H. K.; Keyloun, K. R.; Reid, M. C.; Lafuente-Monasterio, M. J.; Ghidelli-Disse, S.; Leonard, S. E.; He, P.; Jones, J. C.; Krahn, M. M.; Mo, J. S.; Dasari, K. S.; Fox, A. M. W.; Boesche, M.; El Bakkouri, M.; Rivas, K. L.; Leroy, D.; Hui, R.; Drewes, G.; Maly, D. J.; Van Voorhis, W. C.; Ojo, K. K. *PLoS ONE* **2016**, *11*, e0149996.
- (21) Chapman, T. M.; Osborne, S. A.; Wallace, C.; Birchall, K.; Boulloc, N.; Jones, H. M.; Ansell, K. H.; Taylor, D. L.; Clough, B.; Green, J. L.; Holder, A. A. *Journal of Medicinal Chemistry* **2014**, *57*, 3570.
- (22) Large, J. M.; Osborne, S. A.; Smiljanic-Hurley, E.; Ansell, K. H.; Jones, H. M.; Taylor, D. L.; Clough, B.; Green, J. L.; Holder, A. A. *Bioorganic & Medicinal Chemistry Letters* **2013**, *23*, 6019.
- (23) Woodard, C. L.; Li, Z.; Kathcart, A. K.; Terrell, J.; Gerena, L.; Lopez-Sanchez, M.; Kyle, D. E.; Bhattacharjee, A. K.; Nichols, D. A.; Ellis, W.; Prigge, S. T.; Geyer, J. A.; Waters, N. C. *Journal of Medicinal Chemistry* **2003**, *46*, 3877.
- (24) Boulloc, N.; Large, J. M.; Smiljanic, E.; Whalley, D.; Ansell, K. H.; Edlin, C. D.; Bryans, J. S. *Bioorganic & Medicinal Chemistry Letters* **2008**, *18*, 5294.
- (25) Knight, Z. A.; Lin, H.; Shokat, K. M. *Nat Rev Cancer* **2010**, *10*, 130.
- (26) Gamo, F.; Sanz, L.; Vidal, J.; de Cozar, C.; Alvarez, E.; Lavandera, J.; Vanderwall, D.; Green, D.; Kumar, V.; Hasan, S.; Brown, J.; Peishoff, C.; Cardon, L.; Garcia-Bustos, J. *Nature* **2010**, *465*, 305
- (27) Doerig, C.; Abdi, A.; Bland, N.; Eschenlauer, S.; Dorin-Semblat, D.; Fennell, C.; Halbert, J.; Holland, Z.; Nivez, M.-P.; Semblat, J.-P.; Sicard, A.; Reininger, L. *Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics* **2010**, *1804*, 604.
- (28) Dymock, B. W.; See, C. S. *Expert Opinion on Therapeutic Patents* **2013**, *23*, 449.

- (29) Qin, W.-W.; Sang, C.-Y.; Zhang, L.-L.; Wei, W.; Tian, H.-Z.; Liu, H.-X.; Chen, S.-W.; Hui, L. *European Journal of Medicinal Chemistry* **2015**, *95*, 174.
- (30) Kollareddy, M.; Zheleva, D.; Dzubak, P.; Brahmksatriya, P. S.; Lepsik, M.; Hajdusch, M. *Investigational New Drugs* **2012**, *30*, 2411.
- (31) Lotharius, J.; Gamo-Benito, F. J.; Angulo-Barturen, I.; Clark, J.; Connelly, M.; Ferrer-Bazaga, S.; Parkinson, T.; Viswanath, P.; Bhandokar, B.; Rautela, N.; Bharath, S.; Duffy, S.; Avery, V. M.; Möhrle, J. J.; Guy, R. K.; Wells, T. *Malaria Journal* **2014**, *13*, 1.
- (32) Zhou, W.; Ercan, D.; Chen, L.; Yun, C. H.; Li, D.; Capelletti, M.; Cortot, A. B.; Chirieac, L.; Iacob, R. E.; Padera, R.; Engen, J. R.; Wong, K. K.; Eck, M. J.; Gray, N. S.; Janne, P. A. *Nature* **2009**, *462*, 1070.
- (33) Song, X.; He, Y.; Koenig, M.; Shin, Y.; Noel, R.; Chen, W.; Ling, Y. Y.; Feurstein, D.; Lin, L.; Ruiz, C. H.; Cameron, M. D.; Duckett, D. R.; Kamenecka, T. M. *MedChemComm* **2012**, *3*, 238.
- (34) Glenn Noronha; Chi Ching Mak; Jianguo Cao; Joel Renick; Andrew McPherson; Binqi Zeng; Ved P. Pathak; Daniel L. Lohse; John D. Hood; Soll, R. M. Bi-aryl meta-pyrimidine inhibitors of kinases: US 8604042 B2; TargeGen, Inc., San Diego, CA (US) 2011; Vol. US 2011/0212077 A1.
- (35) Johnson, N. W.; Bryan, D. L. Anthranilamide inhibitors of aurora kinase: US 20080182852 A1; Google Patents, 2008.
- (36) Basu, D.; Richters, A.; Rauh, D. *Bioorganic & Medicinal Chemistry* **2015**, *23*, 2767.
- (37) Zuccotto, F.; Ardini, E.; Casale, E.; Angiolini, M. *Journal of Medicinal Chemistry* **2009**, *53*, 2681.
- (38) Liao, J. J.-L. *Journal of Medicinal Chemistry* **2007**, *50*, 409.
- (39) Martin, M. P.; Zhu, J.-Y.; Lawrence, H. R.; Pireddu, R.; Luo, Y.; Alam, R.; Ozcan, S.; Sebt, S. M.; Lawrence, N. J.; Schönbrunn, E. *ACS Chemical Biology* **2012**, *7*, 698.
- (40) Wood, E. R.; Truesdale, A. T.; McDonald, O. B.; Yuan, D.; Hassell, A.; Dickerson, S. H.; Ellis, B.; Pennisi, C.; Horne, E.; Lackey, K.; Alligood, K. J.; Rusnak, D. W.; Gilmer, T. M.; Shewchuk, L. *Cancer Res.* **2004**, *64*, 6652.
- (41) Siu, M.; Pastor, R.; Liu, W.; Barrett, K.; Berry, M.; Blair, W. S.; Chang, C.; Chen, J. Z.; Eigenbrot, C.; Ghilardi, N.; Gibbons, P.; He, H.; Hurley, C. A.; Kenny, J. R.; Cyrus Khojasteh, S.; Le, H.; Lee, L.; Lyssikatos, J. P.; Magnuson, S.; Pulk, R.; Tsui, V.; Ullsch, M.; Xiao, Y.; Zhu, B.-y.; Sampath, D. *Bioorganic & Medicinal Chemistry Letters* **2013**, *23*, 5014.
- (42) Desjardins, R.; Canfield, C.; Haynes, J.; Chulay, J. *Antimicrob Agents Chemother* **1979**, *16*, 710.
- (43) Trager, W.; Jensen, J. *Science* **1976**, *193*, 673.
- (44) Hunt, L.; Jordan, M.; De Jesus, M.; Wurm, F. M. *Biotechnology and Bioengineering* **1999**, *65*, 201.
- (45) Mosmann, T. *Journal of Immunological Methods* **1983**, *65*, 55.
- (46) Kamran, M. Z.; Patil, P.; Gude, R. P. *BioMed Research International* **2013**, *2013*, 15.
- (47) Hu, Y.; Hong, Y.; Xu, Y.; Liu, P.; Guo, D.-H.; Chen, Y. *Apoptosis* **2014**, *19*, 1627.
- (48) Ganster, R. W.; Taylor, B. S.; Shao, L.; Geller, D. A. *Proceedings of the National Academy of Sciences* **2001**, *98*, 8638.
- (49) Liu, R. F.; Zeng, Y.; Lei, Z.; Wang, L.; Yang, H.; Liu, Z.; Zhao, J.; Zhang, H. *International Journal of Oncology* **2014**, *44*, 1643.
- (50) Zhao, M.; Gao, F.-H.; Wang, J.-Y.; Liu, F.; Yuan, H.-H.; Zhang, W.-Y.; Jiang, B. *Lung Cancer* **2011**, *73*, 366.
- (51) John, J. M. *Current Pharmaceutical Design* **2003**, *9*, 2593.
- (52) Daengrot, C.; Rukachaisirikul, V.; Tansakul, C.; Thongpanchang, T.; Phongpaichit, S.; Bowornwiriyan, K.; Sakayaroj, J. *Journal of Natural Products* **2015**, *78*, 615.
- (53) Forsyth, T.; Kearney, P. C.; Kim, B. G.; Johnson, H. W. B.; Aay, N.; Arcalás, A.; Brown, D. S.; Chan, V.; Chen, J.; Du, H.; Epshteyn, S.; Galan, A. A.; Huynh, T. P.; Ibrahim, M. A.; Kane, B.; Koltun, E. S.; Mann, G.; Meyr, L. E.; Lee, M. S.; Lewis, G. L.; Noguchi, R. T.; Pack, M.; Ridgway, B. H.; Shi, X.; Takeuchi, C. S.; Zu, P.; Leahy, J. W.; Nuss, J. M.; Aoyama, R.; Engst, S.; Gendreau, S. B.; Kassees, R.; Li, J.; Lin, S.-H.; Martini, J.-F.; Stout, T.; Tong, P.; Woolfrey, J.; Zhang, W.; Yu, P. *Bioorganic & Medicinal Chemistry Letters* **2012**, *22*, 7653.

## 7. Supplementary Material

Representative NMR and mass spectra have been provided.

### List of Captions

**Table 1.** Representative 2,4-diamino-pyrimidine hits identified from GSK HTS data.<sup>26</sup> *Pf* 3D7 (IC<sub>50</sub>, μM) and HepG2 cytotoxicity (% at 10 μM) are reported for: TCMDC-134115 (**1a**), TCMDC-134116 (**1b**), TCMDC-141384 (**1c**) and TCMDC-141383 (**1d**).

**Table 2.** Sequence similarity, identity to probable *Pf* and host kinases.

**Table 3.** Activities and yields of compounds **1a**, **5a-r**.

**Table 4.** Activity of compounds selected for kinase selectivity and further cytotoxicity assessment.

**Scheme 1.** General scheme for the synthesis of anilines **5a-c**. Reagents and conditions for **3a**: (a) K<sub>2</sub>CO<sub>3</sub>, DMSO, rt, 4-6 h, (b) Pd/C, H<sub>2</sub>, MeOH, rt, overnight.

**Scheme 2.** Synthetic approach used for the preparation of compounds **1a**, **5a-r**. Reagents and conditions for **5a**: (a) DIPEA, n-BuOH, 110 °C overnight, (b) DIPEA, DMF, rt, 4 h; **5i**: (a) DIPEA, n-BuOH, 110 °C overnight, (b) TFA, isopropanol, overnight.

**Fig. 1.** 2,4-diamino-pyrimidines kinase inhibitors; TCMDC 134116,<sup>20</sup> TG101209,<sup>28</sup> SID103904601 ([www.pubchem.com](http://www.pubchem.com)) and covalent inhibitor WZ4002.<sup>32,36</sup>

**Fig. 2.** Schematic (left) and docked model of 2,4 diamino-pyrimidines to PbCDPK1. The binding model of **5k** (carbons in grey) bound to the X-ray crystal structure of PbCDPK1 (3Q5I, magenta). The model was constructed using the JAK2- TG101209 complex (4JIA, cyan).<sup>41</sup> Hydrogen bonds to the hinge and structural waters are indicated by dotted lines.

**Highlights**

Eighteen 2,4-diamino-pyrimidines have been prepared and tested against the Pf. K1 strain. Cytotoxicities in Vero and A549 cells, as well as selected kinase activities, were assessed. **5n** and **5m** are sub- $\mu\text{M}$  inhibitors, with activity comparable to Chloroquine. **5d** and **5k**, are  $\mu\text{M}$  inhibitors of Pf, but with improved cytotoxicity.

ACCEPTED MANUSCRIPT